AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used
in Clinical Diagnostic Kits>
AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used in Clinical Diagnostic Kits
(Thomson Reuters ONE) - Corporate news announcement processed and transmitted by Hugin AS.The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------------------------ MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announcedtoday that its research and diagnostic antibody segment AbD Serotecand Spinreact S.A., a Spanish biotechnology company with more than 30years of experience in research and manufacturing of clinicaldiagnostic reagents, have signed a supply agreement. Initially, theagreement covers the use of two antibodies which Spinreact willincorporate in a series of clinical diagnostic kits. AbD Serotecwill continuously supply Spinreact with antibody material. Financialdetails of the agreement were not disclosed.Dr Josep Puig, Chief Executive Officer of Spinreact, said: "Spinreact is delighted to announce this agreement with AbD Serotec- an industry leader in providing tailored antibodies for researchand diagnostic applications. The fast turn-around in antibodyproduction offered by AbD Serotec, together with the high quality ofthe resulting antibodies, will help accelerate the process ofdevelopment and validation, allowing Spinreact to bring new clinicaldiagnostic reagents for human diseases to the market in the shortestpossible timeframe.""Today's news represents another example of the higher value-addedprojects that AbD Serotec is increasingly pursuing in line with ourstrategy to increase our efforts on the diagnostics side of thebusiness," commented Dieter Feger, Senior Vice President and Head ofMorphoSys's AbD Serotec unit. "We welcome the decision of Spinreactto use AbD Serotec antibodies in its clinical diagnostic reagents. This agreement adds to the growing number of leading diagnosticscompanies that have chosen to partner with AbD Serotec to bringinnovative diagnostic solutions to doctors and patients."Following Swedish diagnostic company Phadia AB, Spinreact is thesecond significant diagnostic company to implement antibodiesprovided by AbD Serotec into a clinical diagnostic kit.Meet AbD Serotec at the 2009 AACC Annual Meeting in Chicago, IL, USAJuly 19th to 23rd at booth No.: 4132.For further information please contact: Dr. Claudia Gutjahr-Löser,Head of Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-122, gutjahr-loeser(at)morphosys.com or Mario Brkulj, SeniorManager Corporate Communications & Investor Relations, Tel: +49 (0)89 / 899 27-454, brkulj(at)morphosys.comAbout MorphoSys:MorphoSys is a publicly traded biotechnology company focused on thegeneration of fully human antibodies as a means to discover anddevelop innovative antibody-based drugs against life-threateningdiseases. MorphoSys's goal is to establish HuCAL as the technology ofchoice for antibody generation in research, diagnostics andtherapeutic applications. The Company currently has therapeutic andresearch alliances with the majority of the world's largestpharmaceutical companies including Boehringer Ingelheim,Centocor/Johnson & Johnson, Novartis, Pfizer and Roche. Within thesepartnerships, more than 50 therapeutic antibody programs are ongoingin which MorphoSys participates through exclusive license andmilestones payments as well as royalties on any end products.Additionally, MorphoSys is active in the antibody research marketthrough its AbD Serotec business unit. The business unit hasoperations in Germany (Munich), the U.S. (Raleigh, NC) and U.K.(Oxford). For further information please visithttp://www.morphosys.com/About SPINREACT:Spinreact, S.A. is a Concateno group company and is a leader in Latexreagents and in Haemostasis. We are developing a new project with newlatex particles and human antibodies. Spinreact, is a manufacturerfor in vitro diagnostic reagents and is producing reagents forBiochemistry, Serology and Immunochemistry. Our introduction inConcateno group of companies has allowed us to provide the latesttechnology for drugs of abuse detection to our customers. Furtherinformation is placed in our website: www.spinreact.comHuCAL®, HuCAL GOLD®, HuCAL PLATINUM® and RapMAT® are registeredtrademarks of MorphoSys AGThis communication contains certain forward-looking statementsconcerning the MorphoSys group of companies. The forward-lookingstatements contained herein represent the judgment of MorphoSys as ofthe date of this release and involve risks and uncertainties. Shouldactual conditions differ from the Company's assumptions, actualresults and actions may differ from those anticipated. MorphoSys doesnot intend to update any of these forward-looking statements as faras the wording of the relevant press release is concerned.http://hugin.info/130295/R/1327883/312942.pdf --- End of Message ---MorphoSys AGLena-Christ-Str. 48 Martinsried / München GermanyWKN: 663200; ISIN: DE0006632003; Index: CDAX, HDAX, Prime All Share, TECH All Share, TecDAX, MIDCAP;Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart, Regulierter Markt in Frankfurter Wertpapierbörse;
Bereitgestellt von Benutzer: hugin
" alt="Interim report January-June 2009>">
" alt="South East Asia Contract Win>">Datum: 09.07.2009 - 07:30 Uhr
Sprache: Deutsch
News-ID 3388
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 413 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbD Serotec and Spinreact Sign Supply Agreement for Antibodies Used
in Clinical Diagnostic Kits>"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
